NBIX Live signaler | Maksimer profitt med Getagraph.com

KJøP 107 min ago

@ $138.59

Utstedt: 1 jul 2024 @ 18:26

Avkastning: 0.85%

Forrige signal: jul 1 - 15:30

Forrige signal: Selg

Avkastning: 0.31 %

Live Chart Being Loaded With Signals

Commentary (1 jul 2024 @ 20:13):
Our systems believe the stock currently is overvalued by -0.07% compare to its pairs and should correct downwards.

Stats
Dagens volum	452 919
Gjennomsnittsvolum	797 922
Markedsverdi	14.07B
EPS	$0.430 ( Q1 \| 2024-05-01 )
Neste inntjeningsdato	( $1.040 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	37.98 (Sector) 42.63 (Industry) 0
ATR14	$4.04 (2.89%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX 0.71%

AKAN -3.46%

ALIM -0.63%

AMPH -3.58%

AMYT 0.00%

ANIP -0.60%

AQST -7.12%

ASRT 0.00%

ATNX 0.00%

AVDL -1.81%

AYTU -4.12%

BFRI -2.00%

BGXX 6.95%

CLVR -1.89%

COLL 1.02%

CPIX -0.65%

CRDL -1.24%

CRON -1.93%

CYTH -3.40%

DCPH 0.00%

DERM -3.37%

DRRX 0.53%

DVAX -0.53%

EGRX -3.57%

EMBC -2.20%

EMBCV -9.33%

EOLS 1.47%

ESPR 5.63%

EVOK -4.54%

FLGC -3.19%

FLXN 0.00%

GHSI -1.68%

HCM 2.98%

HROW 1.68%

HUGE -5.67%

IMCC -3.78%

INCR 1.74%

IRWD 1.07%

ITCI -3.26%

IXHL 0.34%

JUPW 11.76%

KALA -1.11%

KIN 0.11%

KMDA -1.20%

LNTH -0.70%

NBIX 1.53%

NEPT 0.00%

NLTX 1.45%

OGI 0.32%

OPTN 2.42%

ORGO -1.61%

PAHC 1.79%

PCRX 0.21%

PETQ 1.50%

PLXP 0.00%

PPD 0.00%

PROC 3.48%

PRPH -3.35%

PTPI -0.88%

RDHL -0.62%

RDUS 1.38%

REPH -0.48%

RGC -5.03%

RMTI -4.25%

SCTL 0.92%

SCYX -4.95%

SIGA -0.66%

SISI -15.00%

SNDL 0.53%

SNOA 5.51%

SSIC -2.79%

SUPN -0.11%

SXTC 0.00%

THTX -1.41%

TKNO -10.22%

TLGT -13.85%

TLRY 0.60%

TXMD 5.90%

TYHT -3.90%

UPC 3.75%

VTRS -0.19%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-05-31	Delaet Ingrid	Buy	273	Common Stock
2024-05-31	Delaet Ingrid	Sell	273	Common Stock
2024-05-31	Delaet Ingrid	Sell	273	Non-Qualified Stock Option
2024-05-29	Sherwin Stephen A	Buy	25 000	Common Stock
2024-05-29	Sherwin Stephen A	Buy	15 000	Common Stock

INSIDER POWER
-31.10
Last 100 transactions
Buy: 277 011 \| Sell: 532 232

Korrelasjon (AI algo v.1.1b): Overvalued: -0.07% $139.78 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.50 (weak)

Kort: 0.95 (very strong)

Signal:(63) Expect same movement, but be aware

Neurocrine Biosciences Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Neurocrine Biosciences Korrelasjon - Valuta/Råvare

-0.03
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.52
( weak )

0.46
( neutral )

-0.10
( neutral )

Neurocrine Biosciences Økonomi

Annual	2023
Omsetning:	$1.89B
Bruttogevinst:	$1.85B (97.90 %)
EPS:	$2.56

FY	2023
Omsetning:	$1.89B
Bruttogevinst:	$1.85B (97.90 %)
EPS:	$2.56

FY	2022
Omsetning:	$1.49B
Bruttogevinst:	$1.47B (98.44 %)
EPS:	$1.610

FY	2021
Omsetning:	$1.13B
Bruttogevinst:	$1.12B (98.74 %)
EPS:	$0.940

Financial Reports:

No articles found.

Neurocrine Biosciences Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.